<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-27310" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Plasmodium vivax Malaria</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Menkin-Smith</surname>
            <given-names>Lacey</given-names>
          </name>
          <aff>Medical University of South Carolina</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Winders</surname>
            <given-names>Walter T.</given-names>
          </name>
          <aff>Medical University of South Carolina</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Lacey Menkin-Smith declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Walter Winders declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>17</day>
          <month>7</month>
          <year>2023</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-27310.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p>Malaria is a significant global health problem with a substantial disease burden worldwide. In 2019 there were approximately 229 million cases of malaria responsible for about 409000 deaths, the majority on the African continent (WHO World Malaria Report 2020). Malaria results from infection with single-celled parasites belonging to the Plasmodium genus. Five species of Plasmodium are known to cause disease in humans: P. falciparum, P. vivax, P. ovale, P. malariae, and P. knowlesi. Globally, Plasmodium falciparum and Plasmodium vivax account for the majority of cases of malaria. Tis activity reviews the presentation and pathophysiology of malaria and highlights the role of the interprofessional team in its management.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Describe the epidemiology of malaria.</p></list-item><list-item><p>Review the pathophysiology of malaria.</p></list-item><list-item><p>Summarize the treatment options for malaria.</p></list-item><list-item><p>Explain modalities to improve care coordination among interprofessional team members in order to improve outcomes for patients affected by malaria.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=27310&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=27310">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-27310.s2" sec-type="pubmed-excerpt">
        <title>Introduction</title>
        <p>Malaria&#x000a0;is a significant global health problem with a substantial disease burden worldwide. &#x000a0;In 2019 there were approximately 229 million cases of malaria responsible for about 409000 deaths, the majority on the African continent (WHO World Malaria Report 2020). Malaria results from infection with single-celled parasites belonging to the <italic toggle="yes">Plasmodium</italic> genus. Five species of Plasmodium are known to cause disease in humans: <italic toggle="yes">P.&#x000a0;falciparum</italic>, <italic toggle="yes">P. vivax</italic>, <italic toggle="yes">P.&#x000a0;ovale</italic>, <italic toggle="yes">P.&#x000a0;malariae</italic>, and <italic toggle="yes">P.&#x000a0;knowlesi</italic>. Globally, <italic toggle="yes">Plasmodium falciparum</italic> and <italic toggle="yes">Plasmodium vivax</italic> account for the majority of cases of malaria. While <italic toggle="yes">Plasmodium falciparum</italic> is responsible for more deaths, <italic toggle="yes">Plasmodium vivax</italic> is the most widespread of all of the malaria species, can cause severe, even fatal infections and results in significant global morbidity and mortality.</p>
      </sec>
      <sec id="article-27310.s3" sec-type="Etiology">
        <title>Etiology</title>
        <p><italic toggle="yes">Plasmodium vivax</italic> is a protozoal infection spread via the <italic toggle="yes">Anopheles</italic> mosquito.</p>
      </sec>
      <sec id="article-27310.s4" sec-type="Epidemiology">
        <title>Epidemiology</title>
        <p>
<bold>Global Epidemiology&#x000a0;</bold>
</p>
        <p><italic toggle="yes">P. vivax</italic> is the most widespread of the malaria species. More than one-third of the world&#x02019;s population, nearly 2.5 billion people, is at risk of infection with <italic toggle="yes">P. vivax</italic> malaria.<xref ref-type="bibr" rid="article-27310.r1">[1]</xref>&#x000a0; Due to its dormant liver phase, <italic toggle="yes">P. vivax</italic> can survive in colder climates than other species of malaria giving it a wider geographical range, including tropics, subtropics and temperate climates. The highest prevalence is in Latin America and Southeast Asia. According to 2018 WHO World Malaria Report, 74.1% of malaria cases in the Region of the Americas in 2017 resulted from <italic toggle="yes">P. vivax</italic>. While <italic toggle="yes">P. vivax</italic> endemicity overlaps significantly with that of <italic toggle="yes">P. falciparum</italic> in many parts of the world, there are several places in Southeast Asia such as South Korea where <italic toggle="yes">P. vivax</italic> is the exclusive cause of malaria infections.<xref ref-type="bibr" rid="article-27310.r1">[1]</xref> A unique characteristic of the <italic toggle="yes">P. vivax</italic> parasite is that it requires the Duffy antigen on the surface of cells to invade red blood cells, which results in its prevalence being much lower than <italic toggle="yes">P. falciparum</italic> in Africa where the population has low expression of the Duffy antigen.<xref ref-type="bibr" rid="article-27310.r2">[2]</xref> Classic teaching that the lack of Duffy antigen results in resistance to vivax malaria infection has been called into question by more recent studies have shown rare cases of P. vivax infection in Duffy-null Africans.<xref ref-type="bibr" rid="article-27310.r2">[2]</xref><xref ref-type="bibr" rid="article-27310.r3">[3]</xref> Acquisition of immunity to <italic toggle="yes">P. vivax</italic> occurs more rapidly than immunity to P. falciparum. Thus in endemic regions, morbidity tends to peak at an earlier age in <italic toggle="yes">P. vivax</italic>, and adults are more often asymptomatic when infected. Alternatively in low transmission settings risk of severe disease is not dependent on age.<xref ref-type="bibr" rid="article-27310.r4">[4]</xref></p>
        <p>
<bold>In the United States&#x000a0;</bold>
</p>
        <p>According to the CDC, approximately 1,700 cases of malaria are diagnosed&#x000a0;in the United States each&#x000a0;year.&#x000a0;In a 2004 study by Newman et al. that reviewed 185 deaths between 1963 and 2001, 92.7 % were due to P. falciparum with only 3.3% attributed to P. vivax. The study found that failure to take chemoprophylaxis, taking inappropriate or incomplete prophylaxis, and missed diagnosis were common, leading to the finding that 85% of the malaria deaths were preventable.<xref ref-type="bibr" rid="article-27310.r5">[5]</xref></p>
      </sec>
      <sec id="article-27310.s5" sec-type="Pathophysiology">
        <title>Pathophysiology</title>
        <p>Malaria parasites are micro-organisms belonging to the genus <italic toggle="yes">Plasmodium</italic>. The primary host of the parasite is the <italic toggle="yes">Anopheles</italic> mosquito and vertebrates (primarily humans). Malaria parasites are transmitted from the mosquito to its human host in the form of sporozoites during a blood meal. These immediately migrate to the liver where they invade hepatocytes and form schizonts. When these schizonts rupture, <italic toggle="yes">Plasmodium</italic> merozoites are released into the blood. This blood stage coincides with malaria symptoms in the host. <italic toggle="yes">Plasmodium vivax</italic> and ovale have a dormant hypnozoite liver stage. Hypnozoites may remain dormant for months or even years, causing relapsing infection when they finally re-enter the bloodstream.<xref ref-type="bibr" rid="article-27310.r4">[4]</xref> Merozoites of <italic toggle="yes">P. vivax</italic> only infect reticulocytes unlike other species of malaria which will infect all stages of the red blood cell. This exclusive preference for reticulocytes results in significantly lower parasitemia levels in patients infected with <italic toggle="yes">P. vivax</italic> as compared to <italic toggle="yes">P. falciparum</italic>. While parasitemia rarely exceeds 2-3%, <italic toggle="yes">P. vivax</italic> can still result in significant disease due to increased host immune response<xref ref-type="bibr" rid="article-27310.r6">[6]</xref>.&#x000a0; Parasites undergo sexual and asexual multiplication in the human host. The infection spreads when a mosquito takes a blood meal from an infected human continuing the life cycle of the malaria parasite and eventually inoculates its next human host.</p>
      </sec>
      <sec id="article-27310.s6" sec-type="Histopathology">
        <title>Histopathology</title>
        <p>On Giemsa-stained blood smears, <italic toggle="yes">P. vivax</italic> parasites may be present. Because <italic toggle="yes">P. vivax</italic> invades erythrocytes, infected RBCs will appear larger than uninfected cells. Trophozoite may appear as thick, large ameboid rings, about one half the diameter of the RBC and&#x000a0;Schuffner&#x02019;s dots are present. P. vivax schizonts contain<bold>&#x000a0;</bold>12 to 24 merozoites, almost fill the entire cell,&#x000a0;and also contain Schuffner&#x02019;s dots.</p>
      </sec>
      <sec id="article-27310.s7" sec-type="History and Physical">
        <title>History and Physical</title>
        <p>The typical incubation period for vivax malaria is 12 to 17 days, but relapse may occur up to 2 years later from dormant hypnozoites.<xref ref-type="bibr" rid="article-27310.r7">[7]</xref> Classic clinical signs and symptoms of malaria include fever, headache, nausea,&#x000a0;vomiting, body aches, anemia, and jaundice. Making a clinical diagnosis of malaria is sometimes challenging because of the nonspecific symptoms and overlap of signs and symptoms with other febrile illnesses. Due to the parasite life cycle, patients with <italic toggle="yes">P. vivax</italic> malaria tend to have paroxysmal fevers every approximately 42 to 56 hours.<xref ref-type="bibr" rid="article-27310.r8">[8]</xref> Thus <italic toggle="yes">P. vivax</italic> is sometimes referred to as &#x0201c;tertian fever.&#x0201d; Anemia is the most common presenting symptom in adults and children living in <italic toggle="yes">P. vivax</italic> endemic areas. Unlike falciparum malaria, vivax malaria does not tend to cause sequestration; thus multi-system organ failure is less common. However, there are reports of cases of severe vivax malaria.<xref ref-type="bibr" rid="article-27310.r7">[7]</xref><xref ref-type="bibr" rid="article-27310.r8">[8]</xref><xref ref-type="bibr" rid="article-27310.r9">[9]</xref><xref ref-type="bibr" rid="article-27310.r10">[10]</xref> ARDS can occur secondary to host inflammatory immune response to parasitemia.<xref ref-type="bibr" rid="article-27310.r6">[6]</xref><xref ref-type="bibr" rid="article-27310.r8">[8]</xref></p>
      </sec>
      <sec id="article-27310.s8" sec-type="Evaluation">
        <title>Evaluation</title>
        <p>In 2010 the World Health Organization adjusted their guidelines, creating an edict that all cases concerning malaria undergo testing before initiating treatment. Two main diagnostic modalities exist to test for malaria in the clinical setting: Light microscopy and rapid diagnostic tests (RDTs). Polymerase chain reaction (PCR) testing is also available, with more utility in the research setting, it can be used to confirm malaria species after establishing a diagnosis.</p>
        <p>
<bold>Blood Smear</bold>
</p>
        <p>Direct visualization of <italic toggle="yes">P. vivax</italic> parasites on Giemsa-stained blood smears by light microscopy is considered the diagnostic gold standard for the diagnosis of vivax malaria. Three sets of both thick and thin smears should be obtained. Thick smears are more sensitive and are used to detect parasitemia. Thin smears allow for more clear visualization of parasites which helps with speciation. Thin smears can also be used to calculate parasite density. Light microscopy has good sensitivity and is low cost. Limitations to microscopy include the necessity for trained and experienced laboratory technicians, access to a microscope and electricity.<xref ref-type="bibr" rid="article-27310.r11">[11]</xref></p>
        <p>Compared to <italic toggle="yes">P. falciparum</italic>, the number of parasites circulating in the blood of a person infected with <italic toggle="yes">P. vivax</italic> malaria is typically lower, making it more challenging to diagnose. Also, the dormant liver hypnozoite form is undetectable by current diagnostic tools.</p>
        <p>
<bold>Rapid Diagnostic Test (RDT)&#x000a0;</bold>
</p>
        <p>Since the 1990s rapid diagnostic tests (RDTs) have become increasingly popular diagnostic tools, especially in the resource-limited setting.<xref ref-type="bibr" rid="article-27310.r11">[11]</xref> RDTs detect one or more <italic toggle="yes">Plasmodium</italic> antigens in the blood. They offer the benefit of being fast, resulting in about 15 to 20 minutes and do not require a laboratory technician skilled at making and reading blood smears. RDTs are more sensitive at higher parasite loads and may be falsely negative at lower levels of parasitemia.<xref ref-type="bibr" rid="article-27310.r12">[12]</xref></p>
        <p>Most RDTs test for the histidine-rich protein 2 (HRP2) found on <italic toggle="yes">Plasmodium&#x000a0;falciparum</italic>. The sensitivity of these tests is as high as 93-99 percent.<xref ref-type="bibr" rid="article-27310.r13">[13]</xref></p>
        <p>RDTs that can test for <italic toggle="yes">P. vivax</italic> may detect either the P. vivax-pLDH antigen specific to <italic toggle="yes">P. vivax</italic> or pan-pLDH or aldolase antigens common to all Plasmodium species.<xref ref-type="bibr" rid="article-27310.r14">[14]</xref> Studies evaluating the utility of RDTs in detecting P. vivax have shown significantly lower sensitivities.<xref ref-type="bibr" rid="article-27310.r15">[15]</xref><xref ref-type="bibr" rid="article-27310.r16">[16]</xref><xref ref-type="bibr" rid="article-27310.r17">[17]</xref></p>
        <p>In a 2014 Cochran Systematic Review of 47 studies enrolling 22,862 participants, looking at the use of rapid diagnostic tests for diagnosing uncomplicated non-falciparum or&#x000a0;<italic toggle="yes">Plasmodium vivax</italic>&#x000a0;malaria in endemic countries the authors found that RDTs that detect either pan-pLDH or aldolase had sensitivities for non-falciparum malaria that had a range in pooled analyses from 78% (Type 2) to 89%. They found better results for studies compared RDTs that detected a&#x000a0;<italic toggle="yes">P. vivax</italic>&#x000a0;specific antibody line to identify&#x000a0;<italic toggle="yes">P. vivax.&#x000a0; </italic>Compared with microscopy,&#x000a0;the RDTs had pooled sensitivity of 95% (95% CI 86% to 99%) and showed pooled specificity of 99% (95% CI 99% to 100%).<xref ref-type="bibr" rid="article-27310.r12">[12]</xref></p>
        <p>&#x000a0;RDTs can remain positive one month after successful treatment of malaria.<xref ref-type="bibr" rid="article-27310.r18">[18]</xref> In the United States standard practice is to confirm all RDTs with light microscopy.<bold>
</bold></p>
      </sec>
      <sec id="article-27310.s9" sec-type="Treatment / Management">
        <title>Treatment / Management</title>
        <p>Chloroquine remains the mainstay of treatment for uncomplicated vivax malaria. Exceptions to this include infection acquired in areas of chloroquine resistance, primarily Papua New Guinea and Indonesia<xref ref-type="bibr" rid="article-27310.r8">[8]</xref>. According to the CDC appropriate treatment of chloroquine-sensitive uncomplicated vivax malaria includes Chloroquine phosphate or hydroxychloroquine plus primaquine. Dosing is listed below.</p>
        <list list-type="order">
          <list-item>
            <p>Chloroquine phosphate: 600 mg base (=1,000 mg salt) orally immediately, followed by 300 mg base (=500 mg salt) orally at 6, 24, and 48 hours Total dose: 1,500 mg base (=2,500 mg salt)&#x000a0;<italic toggle="yes">OR</italic>&#x000a0;Hydroxychloroquine: 620 mg base (=800 mg salt) orally immediately, followed by 310 mg base (=400 mg salt) orally at 6, 24, and 48 hours</p>
          </list-item>
          <list-item>
            <p>Primaquine phosphate: 30 mg base orally once daily for 14 days</p>
          </list-item>
        </list>
        <p>In regions where P. vivax is chloroquine resistant the CDC offers three possible treatment options: atovaquone-proguanil, quinine plus either tetracycline or doxycycline or mefloquine. Providers should select one of these three options to combine with primaquine.</p>
        <p>Because of the dormant liver phase of <italic toggle="yes">P. vivax</italic>, primaquine must also be added to treatment regimens to treat the hypnozoite phase. Two scenarios in which primaquine is contraindicated include patient with G6PD deficiency and pregnant women. In patients with G6PD deficiency, primaquine may cause severe hemolytic anemia. Decisions for its use in this patient population must occur on a case-by-case basis.<xref ref-type="bibr" rid="article-27310.r19">[19]</xref> In pregnant women, primaquine is contraindicated because of the risk for fetal hemolysis.<xref ref-type="bibr" rid="article-27310.r20">[20]</xref> Delay primaquine treatment until after delivery.<xref ref-type="bibr" rid="article-27310.r21">[21]</xref></p>
        <p>For the treatment of severe malaria worldwide, the WHO recommends the use of intravenous artesunate (2.4mg/kg IV or IM at 0, 12, and 24h then daily). Multiple studies have shown improved efficacy and safety of artesunate in the treatment of severe malaria as compared to previously used intravenous quinidine.<xref ref-type="bibr" rid="article-27310.r22">[22]</xref><xref ref-type="bibr" rid="article-27310.r23">[23]</xref><xref ref-type="bibr" rid="article-27310.r24">[24]</xref> Artesunate currently has no approval from the FDA. Current CDC recommendations for the treatment of severe malaria in the United States include intravenous quinidine plus tetracycline, or doxycycline, or clindamycin. When quinidine is administered patient require continuous cardiac monitoring because of the potential risk of arrhythmia. Intravenous artesunate is available in the United States as an investigational new drug (IND) protocol #76,725 via the CDC (https://www.cdc.gov/malaria/diagnosis_treatment/artesunate.html) for cases of severe malaria refractory to alternative treatment or when IV quinidine is unavailable.</p>
      </sec>
      <sec id="article-27310.s10" sec-type="Differential Diagnosis">
        <title>Differential Diagnosis</title>
        <list list-type="bullet">
          <list-item>
            <p>Dengue fever</p>
          </list-item>
          <list-item>
            <p>Chikungunya</p>
          </list-item>
          <list-item>
            <p>Typhoid Fever</p>
          </list-item>
          <list-item>
            <p>Sepsis from bacteremia</p>
          </list-item>
          <list-item>
            <p>Viral hemorrhagic fever</p>
          </list-item>
          <list-item>
            <p>Leptospirosis</p>
          </list-item>
          <list-item>
            <p>Rickettsial infections</p>
          </list-item>
          <list-item>
            <p>Brucellosis</p>
          </list-item>
          <list-item>
            <p>Influenza</p>
          </list-item>
          <list-item>
            <p>Viral hepatitis</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-27310.s11" sec-type="Prognosis">
        <title>Prognosis</title>
        <p>&#x000a0;If appropriately recognized and treated, <italic toggle="yes">Plasmodium vivax</italic> malaria has a good prognosis and causes significantly fewer complications than falciparum malaria. However, it is recognized that more severe disease can occur. (See below under complications)</p>
      </sec>
      <sec id="article-27310.s12" sec-type="Complications">
        <title>Complications</title>
        <p>While classically <italic toggle="yes">P. vivax</italic> causes lower parasitemia and less severe disease than <italic toggle="yes">P. falciparum</italic>, more recent publications suggest that <italic toggle="yes">P. vivax</italic> is responsible for more severe disease than it was initially attributed. Case reports have demonstrated <italic toggle="yes">P. vivax</italic> causing cerebral malaria, renal failure, acute respiratory distress, and shock.<xref ref-type="bibr" rid="article-27310.r7">[7]</xref><xref ref-type="bibr" rid="article-27310.r8">[8]</xref></p>
        <p>&#x000a0;Another rare complication is splenic rupture which carries a very high mortality rate of up to 80%.<xref ref-type="bibr" rid="article-27310.r25">[25]</xref></p>
        <p>&#x000a0;Pregnant women are at increased risk of adverse outcomes from all forms of malaria and <italic toggle="yes">P. vivax</italic> is no exception. Malaria in pregnancy is associated with higher levels of parasitemia and increases the risk of prematurity, miscarriage, low birth weight, neonatal or maternal death.<xref ref-type="bibr" rid="article-27310.r8">[8]</xref><xref ref-type="bibr" rid="article-27310.r21">[21]</xref></p>
      </sec>
      <sec id="article-27310.s13" sec-type="Deterrence and Patient Education">
        <title>Deterrence and Patient Education</title>
        <p>Malaria prevention takes a multifaceted approach. For travelers, adherence to appropriate malaria prophylaxis medications is key. Also, appropriate clothing (long sleeves and pants) and use of DEET and/or permethrin has been shown to reduce the risk of malaria transmission greatly.<xref ref-type="bibr" rid="article-27310.r26">[26]</xref> Additionally, recognizing that the <italic toggle="yes">Anopheles</italic> mosquitos general bite around dawn and dusk, appropriate behavioral modification may avoid infection as well.&#x000a0; For patients living or staying in endemic regions the use of treated mosquito nets correlates with decreased infection.<xref ref-type="bibr" rid="article-27310.r27">[27]</xref></p>
      </sec>
      <sec id="article-27310.s14" sec-type="Pearls and Other Issues">
        <title>Pearls and Other Issues</title>
        <list list-type="bullet">
          <list-item>
            <p>Plasmodium vivax is the most widespread malaria species with predominance in Latin America and Southeast Asia</p>
          </list-item>
          <list-item>
            <p>The blood smear is the gold standard diagnostic tool for malaria, but in resource-limited clinical settings, rapid diagnostic tests (RDTs) are a reasonable alternative</p>
          </list-item>
          <list-item>
            <p>Treatment decisions need to account for the severity of disease and local patterns of drug resistance</p>
          </list-item>
          <list-item>
            <p>The uncomplicated disease is treatable with chloroquine or hydroxychloroquine in combination with primaquine</p>
          </list-item>
          <list-item>
            <p>In the setting of severe disease outside of the United States, IV artesunate is the treatment of choice</p>
          </list-item>
          <list-item>
            <p>In the United States severe vivax malaria can be treated with intravenous quinidine plus tetracycline, or doxycycline, or clindamycin (artesunate is available in the United States as an investigational new drug (IND) protocol # 76,725 via the CDC)</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-27310.s15" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>Recognizing and diagnosing malaria can be challenging as the symptoms are nonspecific and the diagnosis is uncommon in non-endemic areas. Thus, it is vital that all members of the healthcare team including nurses, midlevel providers, and physicians receive education and training in malaria diagnosis and management. Additionally, skilled laboratory technicians, trained in malaria parasite recognition is key to diagnostic accuracy. If uncertainty exists, a pathologist review may be required. Consultation with infectious disease specialists is often warranted especially in the setting of severe disease.&#x000a0;Communication and coordination between healthcare providers (primary care provider, nurse practitioner, pharmacist) are critical to patient care.</p>
      </sec>
      <sec id="article-27310.s16">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=27310&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=27310">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://mdsearchlight.com/infectious-disease/plasmodium-vivax-malaria/?utm_source=pubmedlink&#x00026;utm_campaign=MDS&#x00026;utm_content=27310">Click here for a simplified version.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/27310/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=27310">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <floats-group id="article-27310.s17">
        <fig id="article-27310.image.f1" position="float" orientation="portrait">
          <caption>
            <p>Life Cycle of the Malaria Parasite Contributed by Wikimedia Commons, National Institutes of Health (NIH) (Public Domain)</p>
          </caption>
          <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="Life_Cycle_of_the_Malaria_Parasite" position="float" orientation="portrait"/>
        </fig>
      </floats-group>
      <floats-group id="article-27310.s18">
        <fig id="article-27310.image.f2" position="float" orientation="portrait">
          <caption>
            <p>Mosquito-Borne Diseases. Mosquitoes are carriers of various diseases, including Zika, dengue fever, West Nile fever, chikungunya, yellow fever, and malaria. National Institute of Allergy and Infectious Diseases, National Institutes of Health</p>
          </caption>
          <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="28526339553_e1691dcb2d_k" position="float" orientation="portrait"/>
        </fig>
      </floats-group>
      <floats-group id="article-27310.s19">
        <fig id="article-27310.image.f3" position="float" orientation="portrait">
          <caption>
            <p>Blood smear malaria Image courtesy S Bhimji MD</p>
          </caption>
          <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="malaria" position="float" orientation="portrait"/>
        </fig>
      </floats-group>
      <ref-list id="article-27310.s20">
        <title>References</title>
        <ref id="article-27310.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Howes</surname>
                <given-names>RE</given-names>
              </name>
              <name>
                <surname>Battle</surname>
                <given-names>KE</given-names>
              </name>
              <name>
                <surname>Mendis</surname>
                <given-names>KN</given-names>
              </name>
              <name>
                <surname>Smith</surname>
                <given-names>DL</given-names>
              </name>
              <name>
                <surname>Cibulskis</surname>
                <given-names>RE</given-names>
              </name>
              <name>
                <surname>Baird</surname>
                <given-names>JK</given-names>
              </name>
              <name>
                <surname>Hay</surname>
                <given-names>SI</given-names>
              </name>
            </person-group>
            <article-title>Global Epidemiology of Plasmodium vivax.</article-title>
            <source>Am J Trop Med Hyg</source>
            <year>2016</year>
            <month>Dec</month>
            <day>28</day>
            <volume>95</volume>
            <issue>6 Suppl</issue>
            <fpage>15</fpage>
            <page-range>15-34</page-range>
            <pub-id pub-id-type="pmid">27402513</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27310.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gunalan</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Lo</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Hostetler</surname>
                <given-names>JB</given-names>
              </name>
              <name>
                <surname>Yewhalaw</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Mu</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Neafsey</surname>
                <given-names>DE</given-names>
              </name>
              <name>
                <surname>Yan</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Miller</surname>
                <given-names>LH</given-names>
              </name>
            </person-group>
            <article-title>Role of Plasmodium vivax Duffy-binding protein 1 in invasion of Duffy-null Africans.</article-title>
            <source>Proc Natl Acad Sci U S A</source>
            <year>2016</year>
            <month>May</month>
            <day>31</day>
            <volume>113</volume>
            <issue>22</issue>
            <fpage>6271</fpage>
            <page-range>6271-6</page-range>
            <pub-id pub-id-type="pmid">27190089</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27310.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gunalan</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Niangaly</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Thera</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Doumbo</surname>
                <given-names>OK</given-names>
              </name>
              <name>
                <surname>Miller</surname>
                <given-names>LH</given-names>
              </name>
            </person-group>
            <article-title>Plasmodium vivax Infections of Duffy-Negative Erythrocytes: Historically Undetected or a Recent Adaptation?</article-title>
            <source>Trends Parasitol</source>
            <year>2018</year>
            <month>May</month>
            <volume>34</volume>
            <issue>5</issue>
            <fpage>420</fpage>
            <page-range>420-429</page-range>
            <pub-id pub-id-type="pmid">29530446</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27310.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Dayananda</surname>
                <given-names>KK</given-names>
              </name>
              <name>
                <surname>Achur</surname>
                <given-names>RN</given-names>
              </name>
              <name>
                <surname>Gowda</surname>
                <given-names>DC</given-names>
              </name>
            </person-group>
            <article-title>Epidemiology, drug resistance, and pathophysiology of <italic>Plasmodium vivax</italic> malaria.</article-title>
            <source>J Vector Borne Dis</source>
            <year>2018</year>
            <season>Jan-Mar</season>
            <volume>55</volume>
            <issue>1</issue>
            <fpage>1</fpage>
            <page-range>1-8</page-range>
            <pub-id pub-id-type="pmid">29916441</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27310.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Newman</surname>
                <given-names>RD</given-names>
              </name>
              <name>
                <surname>Parise</surname>
                <given-names>ME</given-names>
              </name>
              <name>
                <surname>Barber</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Steketee</surname>
                <given-names>RW</given-names>
              </name>
            </person-group>
            <article-title>Malaria-related deaths among U.S. travelers, 1963-2001.</article-title>
            <source>Ann Intern Med</source>
            <year>2004</year>
            <month>Oct</month>
            <day>05</day>
            <volume>141</volume>
            <issue>7</issue>
            <fpage>547</fpage>
            <page-range>547-55</page-range>
            <pub-id pub-id-type="pmid">15466772</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27310.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hemmer</surname>
                <given-names>CJ</given-names>
              </name>
              <name>
                <surname>Holst</surname>
                <given-names>FG</given-names>
              </name>
              <name>
                <surname>Kern</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Chiwakata</surname>
                <given-names>CB</given-names>
              </name>
              <name>
                <surname>Dietrich</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Reisinger</surname>
                <given-names>EC</given-names>
              </name>
            </person-group>
            <article-title>Stronger host response per parasitized erythrocyte in Plasmodium vivax or ovale than in Plasmodium falciparum malaria.</article-title>
            <source>Trop Med Int Health</source>
            <year>2006</year>
            <month>Jun</month>
            <volume>11</volume>
            <issue>6</issue>
            <fpage>817</fpage>
            <page-range>817-23</page-range>
            <pub-id pub-id-type="pmid">16772003</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27310.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Baird</surname>
                <given-names>JK</given-names>
              </name>
            </person-group>
            <article-title>Evidence and implications of mortality associated with acute Plasmodium vivax malaria.</article-title>
            <source>Clin Microbiol Rev</source>
            <year>2013</year>
            <month>Jan</month>
            <volume>26</volume>
            <issue>1</issue>
            <fpage>36</fpage>
            <page-range>36-57</page-range>
            <pub-id pub-id-type="pmid">23297258</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27310.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Price</surname>
                <given-names>RN</given-names>
              </name>
              <name>
                <surname>Tjitra</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Guerra</surname>
                <given-names>CA</given-names>
              </name>
              <name>
                <surname>Yeung</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>White</surname>
                <given-names>NJ</given-names>
              </name>
              <name>
                <surname>Anstey</surname>
                <given-names>NM</given-names>
              </name>
            </person-group>
            <article-title>Vivax malaria: neglected and not benign.</article-title>
            <source>Am J Trop Med Hyg</source>
            <year>2007</year>
            <month>Dec</month>
            <volume>77</volume>
            <issue>6 Suppl</issue>
            <fpage>79</fpage>
            <page-range>79-87</page-range>
            <pub-id pub-id-type="pmid">18165478</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27310.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kochar</surname>
                <given-names>DK</given-names>
              </name>
              <name>
                <surname>Saxena</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Singh</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Kochar</surname>
                <given-names>SK</given-names>
              </name>
              <name>
                <surname>Kumar</surname>
                <given-names>SV</given-names>
              </name>
              <name>
                <surname>Das</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Plasmodium vivax malaria.</article-title>
            <source>Emerg Infect Dis</source>
            <year>2005</year>
            <month>Jan</month>
            <volume>11</volume>
            <issue>1</issue>
            <fpage>132</fpage>
            <page-range>132-4</page-range>
            <pub-id pub-id-type="pmid">15705338</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27310.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Val</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Machado</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Barbosa</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Salinas</surname>
                <given-names>JL</given-names>
              </name>
              <name>
                <surname>Siqueira</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Costa Alecrim</surname>
                <given-names>MG</given-names>
              </name>
              <name>
                <surname>Portillo</surname>
                <given-names>HD</given-names>
              </name>
              <name>
                <surname>Bassat</surname>
                <given-names>Q</given-names>
              </name>
              <name>
                <surname>Monteiro</surname>
                <given-names>WM</given-names>
              </name>
              <name>
                <surname>Guimar&#x000e3;es Lacerda</surname>
                <given-names>MV</given-names>
              </name>
            </person-group>
            <article-title>Respiratory Complications of <italic>Plasmodium vivax</italic> Malaria: Systematic Review and Meta-Analysis.</article-title>
            <source>Am J Trop Med Hyg</source>
            <year>2017</year>
            <month>Sep</month>
            <volume>97</volume>
            <issue>3</issue>
            <fpage>733</fpage>
            <page-range>733-743</page-range>
            <pub-id pub-id-type="pmid">28722625</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27310.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Boyce</surname>
                <given-names>MR</given-names>
              </name>
              <name>
                <surname>O'Meara</surname>
                <given-names>WP</given-names>
              </name>
            </person-group>
            <article-title>Use of malaria RDTs in various health contexts across sub-Saharan Africa: a systematic review.</article-title>
            <source>BMC Public Health</source>
            <year>2017</year>
            <month>May</month>
            <day>18</day>
            <volume>17</volume>
            <issue>1</issue>
            <fpage>470</fpage>
            <pub-id pub-id-type="pmid">28521798</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27310.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Abba</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Kirkham</surname>
                <given-names>AJ</given-names>
              </name>
              <name>
                <surname>Olliaro</surname>
                <given-names>PL</given-names>
              </name>
              <name>
                <surname>Deeks</surname>
                <given-names>JJ</given-names>
              </name>
              <name>
                <surname>Donegan</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Garner</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Takwoingi</surname>
                <given-names>Y</given-names>
              </name>
            </person-group>
            <article-title>Rapid diagnostic tests for diagnosing uncomplicated non-falciparum or Plasmodium vivax malaria in endemic countries.</article-title>
            <source>Cochrane Database Syst Rev</source>
            <year>2014</year>
            <month>Dec</month>
            <day>18</day>
            <volume>2014</volume>
            <issue>12</issue>
            <fpage>CD011431</fpage>
            <pub-id pub-id-type="pmid">25519857</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27310.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Haditsch</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Quality and reliability of current malaria diagnostic methods.</article-title>
            <source>Travel Med Infect Dis</source>
            <year>2004</year>
            <season>Aug-Nov</season>
            <volume>2</volume>
            <issue>3-4</issue>
            <fpage>149</fpage>
            <page-range>149-60</page-range>
            <pub-id pub-id-type="pmid">17291976</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27310.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Maltha</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Gillet</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Jacobs</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Malaria rapid diagnostic tests in endemic settings.</article-title>
            <source>Clin Microbiol Infect</source>
            <year>2013</year>
            <month>May</month>
            <volume>19</volume>
            <issue>5</issue>
            <fpage>399</fpage>
            <page-range>399-407</page-range>
            <pub-id pub-id-type="pmid">23438048</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27310.r15">
          <label>15</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Pattanasin</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Proux</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Chompasuk</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Luwiradaj</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Jacquier</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Looareesuwan</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Nosten</surname>
                <given-names>F</given-names>
              </name>
            </person-group>
            <article-title>Evaluation of a new Plasmodium lactate dehydrogenase assay (OptiMAL-IT) for the detection of malaria.</article-title>
            <source>Trans R Soc Trop Med Hyg</source>
            <year>2003</year>
            <season>Nov-Dec</season>
            <volume>97</volume>
            <issue>6</issue>
            <fpage>672</fpage>
            <page-range>672-4</page-range>
            <pub-id pub-id-type="pmid">16117960</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27310.r16">
          <label>16</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Tjitra</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Suprianto</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Dyer</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Currie</surname>
                <given-names>BJ</given-names>
              </name>
              <name>
                <surname>Anstey</surname>
                <given-names>NM</given-names>
              </name>
            </person-group>
            <article-title>Field evaluation of the ICT malaria P.f/P.v immunochromatographic test for detection of Plasmodium falciparum and Plasmodium vivax in patients with a presumptive clinical diagnosis of malaria in eastern Indonesia.</article-title>
            <source>J Clin Microbiol</source>
            <year>1999</year>
            <month>Aug</month>
            <volume>37</volume>
            <issue>8</issue>
            <fpage>2412</fpage>
            <page-range>2412-7</page-range>
            <pub-id pub-id-type="pmid">10405377</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27310.r17">
          <label>17</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Fransisca</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Kusnanto</surname>
                <given-names>JH</given-names>
              </name>
              <name>
                <surname>Satoto</surname>
                <given-names>TB</given-names>
              </name>
              <name>
                <surname>Sebayang</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Supriyanto</surname>
              </name>
              <name>
                <surname>Andriyan</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Bangs</surname>
                <given-names>MJ</given-names>
              </name>
            </person-group>
            <article-title>Comparison of rapid diagnostic test Plasmotec Malaria-3, microscopy, and quantitative real-time PCR for diagnoses of Plasmodium falciparum and Plasmodium vivax infections in Mimika Regency, Papua, Indonesia.</article-title>
            <source>Malar J</source>
            <year>2015</year>
            <month>Mar</month>
            <day>05</day>
            <volume>14</volume>
            <fpage>103</fpage>
            <pub-id pub-id-type="pmid">25890368</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27310.r18">
          <label>18</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Dalrymple</surname>
                <given-names>U</given-names>
              </name>
              <name>
                <surname>Arambepola</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Gething</surname>
                <given-names>PW</given-names>
              </name>
              <name>
                <surname>Cameron</surname>
                <given-names>E</given-names>
              </name>
            </person-group>
            <article-title>How long do rapid diagnostic tests remain positive after anti-malarial treatment?</article-title>
            <source>Malar J</source>
            <year>2018</year>
            <month>Jun</month>
            <day>08</day>
            <volume>17</volume>
            <issue>1</issue>
            <fpage>228</fpage>
            <pub-id pub-id-type="pmid">29884184</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27310.r19">
          <label>19</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Recht</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Ashley</surname>
                <given-names>EA</given-names>
              </name>
              <name>
                <surname>White</surname>
                <given-names>NJ</given-names>
              </name>
            </person-group>
            <article-title>Use of primaquine and glucose-6-phosphate dehydrogenase deficiency testing: Divergent policies and practices in malaria endemic countries.</article-title>
            <source>PLoS Negl Trop Dis</source>
            <year>2018</year>
            <month>Apr</month>
            <volume>12</volume>
            <issue>4</issue>
            <fpage>e0006230</fpage>
            <pub-id pub-id-type="pmid">29672516</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27310.r20">
          <label>20</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Baird</surname>
                <given-names>JK</given-names>
              </name>
              <name>
                <surname>Hoffman</surname>
                <given-names>SL</given-names>
              </name>
            </person-group>
            <article-title>Primaquine therapy for malaria.</article-title>
            <source>Clin Infect Dis</source>
            <year>2004</year>
            <month>Nov</month>
            <day>01</day>
            <volume>39</volume>
            <issue>9</issue>
            <fpage>1336</fpage>
            <page-range>1336-45</page-range>
            <pub-id pub-id-type="pmid">15494911</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27310.r21">
          <label>21</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kovacs</surname>
                <given-names>SD</given-names>
              </name>
              <name>
                <surname>Rijken</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>Stergachis</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Treating severe malaria in pregnancy: a review of the evidence.</article-title>
            <source>Drug Saf</source>
            <year>2015</year>
            <month>Feb</month>
            <volume>38</volume>
            <issue>2</issue>
            <fpage>165</fpage>
            <page-range>165-81</page-range>
            <pub-id pub-id-type="pmid">25556421</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27310.r22">
          <label>22</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Dondorp</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Nosten</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Stepniewska</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Day</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>White</surname>
                <given-names>N</given-names>
              </name>
              <collab>South East Asian Quinine Artesunate Malaria Trial (SEAQUAMAT) group</collab>
            </person-group>
            <article-title>Artesunate versus quinine for treatment of severe falciparum malaria: a randomised trial.</article-title>
            <source>Lancet</source>
            <string-date>2005 Aug 27-Sep 2</string-date>
            <volume>366</volume>
            <issue>9487</issue>
            <fpage>717</fpage>
            <page-range>717-25</page-range>
            <pub-id pub-id-type="pmid">16125588</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27310.r23">
          <label>23</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Jones</surname>
                <given-names>KL</given-names>
              </name>
              <name>
                <surname>Donegan</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Lalloo</surname>
                <given-names>DG</given-names>
              </name>
            </person-group>
            <article-title>Artesunate versus quinine for treating severe malaria.</article-title>
            <source>Cochrane Database Syst Rev</source>
            <year>2007</year>
            <month>Oct</month>
            <day>17</day>
            <issue>4</issue>
            <fpage>CD005967</fpage>
            <pub-id pub-id-type="pmid">17943870</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27310.r24">
          <label>24</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hess</surname>
                <given-names>KM</given-names>
              </name>
              <name>
                <surname>Goad</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Arguin</surname>
                <given-names>PM</given-names>
              </name>
            </person-group>
            <article-title>Intravenous artesunate for the treatment of severe malaria.</article-title>
            <source>Ann Pharmacother</source>
            <year>2010</year>
            <season>Jul-Aug</season>
            <volume>44</volume>
            <issue>7-8</issue>
            <fpage>1250</fpage>
            <page-range>1250-8</page-range>
            <pub-id pub-id-type="pmid">20551300</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27310.r25">
          <label>25</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hartley</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Oxford handbook of tropical medicine.</article-title>
            <source>BMJ</source>
            <year>2000</year>
            <month>Mar</month>
            <day>11</day>
            <volume>320</volume>
            <issue>7236</issue>
            <fpage>721A</fpage>
            <pub-id pub-id-type="pmid">10710604</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27310.r26">
          <label>26</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Goodyer</surname>
                <given-names>LI</given-names>
              </name>
              <name>
                <surname>Croft</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Frances</surname>
                <given-names>SP</given-names>
              </name>
              <name>
                <surname>Hill</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Moore</surname>
                <given-names>SJ</given-names>
              </name>
              <name>
                <surname>Onyango</surname>
                <given-names>SP</given-names>
              </name>
              <name>
                <surname>Debboun</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Expert review of the evidence base for arthropod bite avoidance.</article-title>
            <source>J Travel Med</source>
            <year>2010</year>
            <season>May-Jun</season>
            <volume>17</volume>
            <issue>3</issue>
            <fpage>182</fpage>
            <page-range>182-92</page-range>
            <pub-id pub-id-type="pmid">20536888</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27310.r27">
          <label>27</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Pryce</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Richardson</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Lengeler</surname>
                <given-names>C</given-names>
              </name>
            </person-group>
            <article-title>Insecticide-treated nets for preventing malaria.</article-title>
            <source>Cochrane Database Syst Rev</source>
            <year>2018</year>
            <month>Nov</month>
            <day>06</day>
            <volume>11</volume>
            <issue>11</issue>
            <fpage>CD000363</fpage>
            <pub-id pub-id-type="pmid">30398672</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
